MKM Partners Maintains Buy on Isos Acquisition, Raises Price Target to $14

MKM Partners analyst Eric Handler maintains Isos Acquisition (NYSE:ISOS) with a Buy and raises the price target from $13 to $14.

byBenzinga Newsdesk

November 16, 2021

1 minute read

MKM Partners analyst Eric Handler maintains Isos Acquisition (NYSE:ISOS) with a Buy and raises the price target from $13 to $14.

Benchmark Initiates Coverage On Marathon Oil with Buy Rating, Announces Price Target of $19

By Benzinga Newsdesk

Today, 11:22 PM

Benchmark analyst Subash Chandra initiates coverage on Marathon Oil (NYSE:MRO) with a Buy rating and announces Price Target of $19.

MRO

Matinas BioPharma Announces Positive Opinion By The European Medicines Agency On Orphan Drug Designation For MAT2203 For The Treatment Of Cryptococcosis

By Benzinga Newsdesk

Today, 11:22 PM

Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform

MTNB

Sangamo Therapeutics Q3 EPS $(0.34) Beats $(0.35) Estimate, Sales $26.46M Miss $26.59M Estimate

By Benzinga Newsdesk

Today, 11:22 PM

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 3.03 percent decrease over losses of $(0.33) per share

SGMO

Nxt-ID Shares Up 7% After Hours; Earlier Co. 8-K Showed Results Of Annual Meeting Of Shareholders; BZ NOTE: Results Of Annual Meeting Of Shareholders Do Not Usually Impact Stocks

By Benzinga Newsdesk

Today, 11:22 PM

Nxt-ID, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) on December 17, 2021. Set forth below are the three proposals that were voted on at the

NXTD

MKM Partners Maintains Buy on Isos Acquisition, Raises Price Target to $14

Related Posts

Benchmark Initiates Coverage On Marathon Oil with Buy Rating, Announces Price Target of $19

Matinas BioPharma Announces Positive Opinion By The European Medicines Agency On Orphan Drug Designation For MAT2203 For The Treatment Of Cryptococcosis

Sangamo Therapeutics Q3 EPS $(0.34) Beats $(0.35) Estimate, Sales $26.46M Miss $26.59M Estimate

Nxt-ID Shares Up 7% After Hours; Earlier Co. 8-K Showed Results Of Annual Meeting Of Shareholders; BZ NOTE: Results Of Annual Meeting Of Shareholders Do Not Usually Impact Stocks